

Aide memoire

June 2026

Stockholm, 2 June 2026. Sobi (NASDAQ: SOBI) has compiled the following items and prior disclosures for consideration to assist in the financial modelling of the Company's Q2 2026 results.

Sobi Q1 2026 communications can be found on sobi.com/investors.

Business Items

Overall Q1 2026 revenue performance and general comments

Total revenue for Q1 2026 was SEK 7,184 M and increased by 24 per cent at CER. Strong growth from Altuvocet, Doptelet, Gamifant and Kineret was partially offset by lower sales for Elocta.

During Q2 2026 Sobi announced the positive topline data for the REDUCE-2 Phase 3 study of pozdeutinurad in gout. Additionally, Sobi held its AGM where Mikael Dolsten and Åsa Riisberg were elected as new Board members.

Please note the following previously communicated product performances (growth at CER):

Haematology

- **Elocta and Altuvocet:** Altuvocet sales were SEK 1,240 M (455) in the Q1 2026, following strong launches and initial sales in 27 countries led by Germany, France, the UK and Spain. Elocta sales were SEK 787 M (1,272) in the Q1 2026 and decreased by 33 per cent at CER. Sales of Elocta were as expected impacted by switch of patients to Altuvocet in launched markets. The combined haemophilia A sales increased 25 per cent at CER in Q1 2026.
- **Alprolix:** sales were SEK 539 M in Q1 2026 and decreased by 1 per cent at CER. The decrease was driven by phasing in the international region offsetting growth in other markets.
- **Doptelet:** revenue was SEK 1,433 M in Q1 2026 and increased by 44 per cent at CER. The strong performance was driven by increased uptake across markets.
- **Aspaveli/Empaveli:** sales were SEK 371 M in Q1 2026 and increased by 21 per cent at CER mainly reflecting new nephrology patients and phasing in the international region.
- **Vonjo:** sales were SEK 278 M in the Q1 2026 and increased by 6 per cent at CER. The growth was driven by stocking in the US, partly offset by order phasing in the international region.
- **Zynlonta:** sales were SEK 46 M in Q1 2026.

Immunology

- **Kineret:** sales were SEK 779 M in Q1 2026 and increased by 21 per cent at CER, driven by increased demand across the North America and International regions.
- **Gamifant:** sales were SEK 734 M in Q1 2026 and increased by 47 per cent at CER, driven by new patients treated for MAS in Still's disease in the US and an increase in the total number of patients on treatment.
- **Beyfortus:** Royalty earned from Sanofi's sales of Beyfortus in the US was SEK 130 M in Q1 2026.

Specialty care

Specialty Care revenue was SEK 354 M in Q1 2026 and increased by 24 per cent at CER.

Financials

OPEX

- Selling and administrative expenses were SEK 2,621 M (2,679) in Q1 2026 (Q1 2025), including amortisation of SEK 744 M (903). IAC amounted to SEK -53 M (—). Excluding these costs and amortisation, the selling and administrative expenses increased by 12 per cent at CER.
- R&D expenses were SEK 948 M (834) in Q1 2026 (Q1 2025). IAC amounted to SEK 20 M (—). Excluding these costs, the R&D expenses increased 22 per cent at CER.

Estimated currency impact

- Based on the evolution of foreign currencies, the preliminary estimate is a negative impact on Sobi's Q2 2026 revenue of between 1% and 3% compared to constant exchange rates.

Tax rate

- Income tax was SEK -363 M (-221) in the quarter, corresponding to an effective tax rate (ETR) of 21.6 per cent (20.1) in Q1 2026. The higher effective tax rate was mainly driven by an increased impact from higher tax jurisdictions.

Number of Shares

- Average number of ordinary shares after dilution (excluding treasury shares) was 349,357,541 in Q1 2026.

Outlook 2026

- Revenue anticipated to grow by a low double-digit percentage at CER.
- Adjusted EBITA margin is anticipated to be in the mid-30s percentage of revenue.

Forward-looking statements

This document contains certain forward-looking statements with respect to certain of the Company's current expectations and projections about future events. These statements, which sometimes use words such as "intend," "proposed," "plan," "expect," and words of similar meaning, reflect management's beliefs and expectations and involve a number of risks, uncertainties and assumptions that could cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statement. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The information contained in this presentation is subject to change without notice and, except as required by applicable law, the Company does not assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained in it. You should not place undue reliance on forward-looking statements, which speak only as at the date of this presentation.

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia and Australia. In 2025, revenue amounted to SEK 28 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and [LinkedIn](#).

Contacts

For details on how to contact the Sobi Investor Relations Team, please click [here](#). For Sobi Media contacts, click [here](#).

Gerard Tobin
Head of Investor Relations